Table II.
Prevention of Hepatocarcinogenesis by Anti-FasL mAb Treatment
| Mouse ID | Mo after spl. transfer |
Age (mo) at killing |
No. of tumors |
Largest tumor (mm)a |
Tumor histology |
|---|---|---|---|---|---|
| Treated with PBS or control hamster IgG (intraperitoneally) | |||||
| 110 | 9 | 16 | 1 | 2 | Adenoma |
| 113 | 8 | 15 | 2 | 2 | Adenoma |
| 189 | 9 | 15 | 1 | 4 | Adenoma |
| 266 | 13 | 17 | 1 | 11 | HCC |
| 276 | 15 | 18 | 1 | 5 | HCC |
| 323 | 15 | 18 | 2 | 11 | HCC |
| 341 | 15 | 18 | 4 | 3 | HCC |
| 343 | 14 | 17 | 11 | 3 | HCC |
| 391 | 15 | 17 | 3 | 7 | HCC |
| 6 | 17 | 19 | 1 | 10 | HCC |
| 55 | 17 | 19 | 3 | 10 | HCC |
| 59 | 20 | 22 | 2 | 20 | HCC |
| Treated with anti-FasL mAb (intraperitoneally) | |||||
| 33 | 7 | 17 | 0 | 0 | |
| 93 | 7 | 12 | 0 | 0 | |
| 96 | 7 | 12 | 0 | 0 | |
| 135 | 9 | 16 | 0 | 0 | |
| 136 | 13 | 20 | 1 | 3 | Adenoma |
| 147 | 13 | 20 | 0 | 0 | |
| 179 | 12 | 16 | 0 | 0 | |
| 287 | 18 | 20 | 0 | 0 | |
| 243 | 17 | 23 | 1 | 12 | HCC |
| 258 | 18 | 21 | 0 | 0 | |
| 283 | 17 | 19 | 0 | 0 | |
| 349 | 12 | 14 | 0 | 0 | |
| 351 | 15 | 17 | 0 | 0 | |
| 360 | 15 | 17 | 0 | 0 | |
| 78 | 23 | 25 | 0 | 0 | |
spl., splenocyte.
a
Diameter in the major axis.